IFM Investors Pty Ltd raised its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 16.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 219,017 shares of the biopharmaceutical company’s stock after buying an additional 30,652 shares during the quarter. IFM Investors Pty Ltd’s holdings in Bristol-Myers Squibb were worth $13,586,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. CCM Investment Advisers LLC lifted its position in Bristol-Myers Squibb by 0.3% during the 3rd quarter. CCM Investment Advisers LLC now owns 156,259 shares of the biopharmaceutical company’s stock valued at $9,420,000 after acquiring an additional 407 shares during the period. Chesley Taft & Associates LLC lifted its holdings in shares of Bristol-Myers Squibb by 2.9% during the fourth quarter. Chesley Taft & Associates LLC now owns 22,866 shares of the biopharmaceutical company’s stock valued at $1,418,000 after purchasing an additional 645 shares during the last quarter. WFA of San Diego LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth approximately $631,000. Ninety One UK Ltd purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $13,165,000. Finally, TIAA FSB grew its stake in shares of Bristol-Myers Squibb by 5.2% in the 3rd quarter. TIAA FSB now owns 513,245 shares of the biopharmaceutical company’s stock worth $30,943,000 after buying an additional 25,582 shares during the last quarter. 72.41% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE BMY traded down $0.70 during midday trading on Wednesday, hitting $64.73. 9,470,630 shares of the stock traded hands, compared to its average volume of 12,710,041. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.58 and a current ratio of 1.67. Bristol-Myers Squibb has a one year low of $45.76 and a one year high of $68.34. The firm has a market capitalization of $146.46 billion, a P/E ratio of -588.40, a PEG ratio of 0.94 and a beta of 0.67. The firm has a 50-day moving average of $62.09 and a two-hundred day moving average of $74.86.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.14. The firm had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.33 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The business’s revenue for the quarter was up 75.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.17 EPS. Equities analysts forecast that Bristol-Myers Squibb will post 6.35 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 1st. Shareholders of record on Monday, January 4th will be given a $0.49 dividend. The ex-dividend date is Thursday, December 31st. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.45. This represents a $1.96 annualized dividend and a yield of 3.03%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.79%.

Several research firms have commented on BMY. Berenberg Bank started coverage on Bristol-Myers Squibb in a report on Tuesday, September 29th. They issued a “buy” rating and a $73.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Bristol-Myers Squibb from $74.00 to $78.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Raymond James reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 25th. Gabelli cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday, November 6th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, November 10th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $73.75.

In other Bristol-Myers Squibb news, EVP Rupert Vessey sold 57,591 shares of the company’s stock in a transaction dated Thursday, November 19th. The stock was sold at an average price of $61.30, for a total value of $3,530,328.30. Following the completion of the sale, the executive vice president now owns 46,142 shares in the company, valued at $2,828,504.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Adam Dubow sold 900 shares of the firm’s stock in a transaction dated Tuesday, November 24th. The stock was sold at an average price of $63.39, for a total value of $57,051.00. Following the completion of the transaction, the senior vice president now directly owns 15,186 shares in the company, valued at approximately $962,640.54. The disclosure for this sale can be found here. Insiders have sold a total of 71,915 shares of company stock worth $4,410,814 in the last quarter. Corporate insiders own 0.14% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.